StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Sage Therapeutics (SAGE) Weakness is a Buying Opportunity - RBC
April 23, 2018 10:20 AM
RBC Capital analyst Brian Abrahams sees weakness in Sage Therapeutics (NASDAQ: SAGE) on Friday, related to insider selling and a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
BMO Capital on SAGE Therapeutics (SAGE): 'Another Important Milestone Achieved with Brexanolone Filing for PPD'
April 23, 2018 10:23 AM
SAGE Therapeutics (SAGE) Submits NDA to FDA for Intravenous Brexanolone in Treatment of Postpartum Depression
April 23, 2018 7:03 AM
Sage Therapeutics Submits New Drug Application to U.S. FDA for Intravenous Brexanolone in the Treatment of Postpartum Depression
April 23, 2018 7:00 AM
SAGE Therapeutics (SAGE) Defended at Raymond James, Says Selloff is Overreaction
April 20, 2018 12:05 PM
Form 4 Sage Therapeutics, Inc. For: Apr 17 Filed by: STARR KEVIN P
April 19, 2018 4:36 PM
